Bharat Parenterals Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
Published 15 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹1.0K Cr
Standalone business: - Expected revenue growth of 10% to 15% in FY '27, based on INR 230 crores base. Innoxel Lifesciences: Expected revenue growth of 35%-45% in FY '27 with EBITDA margins of 20%-25%.
From Bharat Parenterals Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
📊 Revenue & Sales Performance
Rank 2- →Standalone business:
- → - Expected revenue growth of 10% to 15% in FY '27, based on INR 230 crores base.
- → - Full recovery and crossing FY '25 numbers anticipated by FY '28.
- → - Long-term peak revenue target of INR 400-500 crores by 2030.
- → - Growth driven by Southeast Asia, Africa, and MENA regions.
- →Innoxel Lifesciences:
- → - Revenue growth of 35% to 45% expected in FY '27.
- → - Commercial CMO supply starting Q2 FY '27 with 2-3 products commercializing.
- → - 10 new filings and 20 partner deals planned in FY '27.
- → - Strong manufacturing revenues and out-licensing milestones expected to start FY '28.
- →Varenyam Healthcare:
- → - Revenue growth of 20% to 25% forecast in FY '27.
- → - Expansion of field force to over 250 people.
- → - Introduction of 7 new products including India's first made-in-India Sugammadex.
- →Varenyam Biolifesciences:
- → - Pre-revenue through FY '27.
- → - Facility commissioning by Sept 2027 and manufacturing validation by March 2028.
- → - First commercial supplies expected Q4 FY '29.
See what Bharat Parenterals Ltd said on profitability & margins — free account, 30 seconds.
🏗️ Capital Expenditure Plans
Yes- →Varenyam Biolifesciences (VBPL) is undergoing capital investment with an approved budget of around INR 160 crores for building a complex injectable manufacturing facility.
- →As of FY '26 year-end, around INR 33 crores has been spent (20% of the budget).
- →Key milestones include commissioning manufacturing lines by September 2027 and validation by March 2028.
- →The facility aims for first regulatory filing under EUGMP in Q1 FY '29 and commercial supply by Q4 FY '29.
- →Standalone business completed facility upgrades last year including general injectable vial line, water system in beta-lactam block, preparing for upcoming PIC/S and EUGMP inspections in FY '27. These were one-time capex activities causing some production downtime.
- →No fresh capital expenditure is currently needed to grow the standalone business by 10-15% in FY '27 due to existing capacity headroom.
See what Bharat Parenterals Ltd said on fundraising & capital structure — free account, 30 seconds.
📋 Order Book & Pipeline
No information- →The standalone business has an order book of INR 171 crores, providing reasonable visibility for FY '27.
- →The $27 million ($27 million approx.) tender order for high-demand pharmaceutical products in the standalone business was delayed but has started supply in 2026, with 90% expected to be covered within the year.
- →Innoxel has 20 targeted new partner deals in the pipeline, with 10 in advanced stages of discussions and due diligence.
- →Innoxel expects to file 10 new products in FY '27.
- →Varenyam Biolifesciences is pre-revenue through FY '27, focusing on commissioning and regulatory milestones, with first commercial supply expected in Q4 FY '29.
- →The standalone business growth is expected at 10%-15% in FY '27, supported by existing order book and market expansions.
Key Metrics
2 of 5 growth signals positive in the Q4 FY26 call.
Revenue
Margin
Capex
Fundraise
Order Book
How does Bharat Parenterals Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureSee full Pharmaceuticals & Biotechnology sector rankings
Price
₹1,397
Market Cap
₹1.0K Cr
Bharat Parenterals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹100 Cr, net profit ₹-8 Cr.
Full financials →Continue your research
What Bharat Parenterals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Torrent Pharma. (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
- Kwality Pharma (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
- RPG LifeScience. (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
- Sai Parenteral's (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…
Frequently Asked Questions
What were Bharat Parenterals Ltd Q4 FY26 results?
Standalone business: - Expected revenue growth of 10% to 15% in FY '27, based on INR 230 crores base. Innoxel Lifesciences: Expected revenue growth of 35%-45% in FY '27 with EBITDA margins of 20%-25%.
What is Bharat Parenterals Ltd share price analysis?
Bharat Parenterals Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of N/A with a market cap of ₹1,007 Cr. Investors should review the full earnings analysis for detailed insights.
Is Bharat Parenterals Ltd planning capital expenditure?
Varenyam Biolifesciences (VBPL) is undergoing capital investment with an approved budget of around INR 160 crores for building a complex injectable manufacturing facility. - As of FY '26 year-end, around INR 33 crores has been spent (20% of the budget). - Key milestones include commissioning manufacturing lines by September 2027 and validation by March 2028. - The facility aims for first regulatory filing under EUGMP in Q1 FY '29 and commercial supply by Q4 FY '29. - Standalone business completed facility upgrades last year including general injectable vial line, water system in beta-lactam block, preparing for upcoming PIC/S and EUGMP inspections in FY '27.
Keep Bharat Parenterals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.